Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation

  • Loredana Ruggeri
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Marusca Capanni
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Myriam Casucci
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Isabella Volpi
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Antonella Tosti
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Katia Perruccio
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Elena Urbani
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Robert S. Negrin
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Massimo F. Martelli
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.
  • Andrea Velardi
    From the Division of Hematology and Clinical Immunology, the Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; and the Division of Bone Marrow Transplantation, the Department of Medicine, Stanford University, Stanford, CA 94305.

抄録

<jats:p>Because of the expression of inhibitory receptors (KIR) for major histocompatibility complex (MHC) class I allotypes, a person’s natural killer (NK) cells will not recognize and will, therefore, kill cells from individuals lacking his/her KIR epitopes. This study investigated the role of NK cell alloreactivity in human HLA haplotype-mismatched hematopoietic stem cell transplantation and, specifically, the role of the three major NK specificities, ie, those for HLA-C group 1, HLA-C group 2, and HLA-Bw4 alleles. In 20 of 60 donor-recipient pairs, KIR epitope incompatibility and functional analyses of donor NK cell clones predicted donor NK cells could cause graft-versus-host (GVH)/graft-versus-leukemia (GVL) reactions. NK cell clones of donor origin were obtained from transplanted recipients and tested for lysis of recipient’s cryopreserved pretransplant lymphocytes. Despite the absence of GVH disease, we detected high frequencies of NK clones which killed recipient’s target cells. Lysis followed the rules of NK cell alloreactivity, being blocked only by the MHC class I KIR epitope which was missing in the recipient. The alloreactive NK clones also killed the allogeneic leukemia. Transplants from these KIR epitope incompatible donors had higher engraftment rates. Therefore, a GVL effector and engraftment facilitating mechanism, which is independent of T-cell–mediated GVH reactions, may be operational in HLA mismatched hematopoietic cell transplants.</jats:p>

収録刊行物

  • Blood

    Blood 94 (1), 333-339, 1999-07-01

    American Society of Hematology

被引用文献 (11)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ